Nuwellis highlights pediatric ultrafiltration therapy case study at ISHLT 2026, advancing heart failure treatment.

Nuwellis, Inc. showcased a case study at the ISHLT 2026 meeting demonstrating the use of Aquadex ultrafiltration therapy in a pediatric patient with chemotherapy-induced heart failure and fluid overload. The study showed the therapy's safety and effectiveness when traditional diuretics failed, improving pre- and post-operative outcomes. This highlights the growing adoption of precision ultrafiltration for managing fluid in complex pediatric cardiorenal cases. Nuwellis aims to establish Aquadex as a standard care tool in pediatric heart failure treatment.